Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methyldopa

FDA-approved product (tablet, oral), marketed as Aldomet, Methyldopa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Methyldopa
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Methyldopa
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA21.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Methyldopa in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methyldopa with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy

    NCT00329511 · start 2004-09

    Registered record
    Registry ID
    NCT00329511
    Conditions
    Hypertension
    Interventions
    methyldopa vs. clonidine; clonidine patch
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2004-09
    Completion
    2008-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionmethyldopa vs. clonidine; clonidine patch
    PhaseNot applicable
    Registry statusWithdrawn

  • Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.

    NCT00174239 · start 2004-07

    Registered record
    Registry ID
    NCT00174239
    Conditions
    Parkinson Disease
    Interventions
    cabergoline; controlled-release levodopa / carbidopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-07
    Completion
    2005-09
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    Interventioncabergoline; controlled-release levodopa / carbidopa
    PhasePhase 4
    Registry statusTerminated

  • Treatment of Orthostatic Hypotension in Autonomic Failure

    NCT00223691 · start 2002-03

    Registered record
    Registry ID
    NCT00223691
    Conditions
    Autonomic Failure; Orthostatic Hypotension
    Interventions
    Atomoxetine; Acarbose; Pyridostigmine Bromide; Yohimbine; Midodrine HCl; placebo; Modafinil; Octreotide; water intake; Diphenhydramine Hydrochloride; Ranitidine HCL; Tranylcypromine; Ergotamine/ Caffeine; Celecoxib; Pseudoephedrine; Methylphenidate; Indomethacin; Ibuprofen; Oxymetazoline 0.05% nasal solution; Bovril; Acetazolamide; Rivastigmine tartrate; Carbidopa/levodopa; Inflatable abdominal binder; inflatable abdominal binder (sham)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-03
    Completion
    2017-01
    Enrolment
    389

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutonomic Failure; Orthostatic Hypotension
    InterventionAtomoxetine; Acarbose; Pyridostigmine Bromide; Yohimbine +21 more
    PhasePhase 1
    Registry statusCompleted

  • Treatment of Supine Hypertension in Autonomic Failure

    NCT00223717 · start 2001-01

    Registered record
    Registry ID
    NCT00223717
    Conditions
    Hypertension
    Interventions
    Clonidine; Nitroglycerin transdermal; Dipyridamole/ Aspirin (Aggrenox); Desmopressin (DDAVP); Sildenafil; Nifedipine; Hydralazine; Hydrochlorothiazide; Placebo; Bosentan; Diltiazem; Eplerenone; guanfacine; L-arginine; captopril; carbidopa; losartan; metoprolol tartrate; nebivolol hydrochloride; prazosin hydrochloride; tamsulosin hydrochloride; Head-up tilt.; aliskiren; Local heat stress
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-01
    Completion
    2017-01
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionClonidine; Nitroglycerin transdermal; Dipyridamole/ Aspirin (Aggrenox); Desmopressin (DDAVP) +20 more
    PhasePhase 1
    Registry statusCompleted

  • The Pathophysiology of Orthostatic Hypotension

    NCT00748059 · start 1996-12

    Registered record
    Registry ID
    NCT00748059
    Conditions
    Autonomic Nervous System Diseases; Orthostatic Hypotension; Dopamine Beta-Hydroxylase Deficiency; Orthostatic Intolerance
    Interventions
    Standing or upright tilt; Microneurography; QSweat; neck cuff stimulation; phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine; clonidine,yohimbine,metoclopramide,alpha-methyldopa; BodPod; Eye exam; Sleep study; Pain response testing; Metabolic chamber; Brain function studies; Bicycle Exercise Test
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1996-12
    Completion
    2020-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutonomic Nervous System Diseases; Orthostatic Hypotension; Dopamine Beta-Hydroxylase Deficiency; Orthostatic Intolerance
    InterventionStanding or upright tilt; Microneurography; QSweat; neck cuff stimulation +9 more
    PhasePhase 1
    Registry statusCompleted